Is ivermectin ready to be part of a public health policy for COVID-19 prophylaxis?
- PMID: 33558858
- PMCID: PMC7859718
- DOI: 10.1016/j.eclinm.2021.100744
Is ivermectin ready to be part of a public health policy for COVID-19 prophylaxis?
Conflict of interest statement
All authors declare no conflict of interest.
References
-
- Johns Hopkins University, Medicine. COVID Resource Center. (Online). https://coronavirus.jhu.edu/map.html (Reviewed01/10/2021).
-
- Swissinfo.ch. [Recomiendan uso de Ivermectina para combatir la covid-19 en Honduras]. (Online). https://www.swissinfo.ch/spa/coronavirus-honduras_recomiendan-uso-de-ive... (Reviewed01/10/2021).
-
- Chaccour C., Casellas A., Blanco-Di Matteo A. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine. 2021 doi: 10.1016/j.eclinm.2020.100720. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources